<DOC>
	<DOCNO>NCT01540292</DOCNO>
	<brief_summary>This project aim assess safety efficacy allogeneic Mesenchymal stem Cell ( MSC ) Crohn 's disease refractory intolerant conventional therapy . Twenty patient active refractory Crohn 's disease define Crohn 's Disease Activity Index ( CDAI ) &gt; 220 despite conventional treatment include 4 year phase I-II trial . This pilot open label trial . Patients treat 2 successive injection allogeneic MSC baseline 4 week later . Patients follow week 2 , 4 , 8 12 .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Therapy Treatment Severe Refractory Inflammatory and/or Autoimmune Disorders</brief_title>
	<detailed_description>1 . Collection expansion MSC Bone marrow collection MSC expansion culture carry Laboratory Cell Gene Therapy ( LTCG ) University Liège . Bone marrow ( 50 ml ) collect unrelated donor local anesthesia , mononuclear cell isolate , culture total 4 week . After sufficient number passage , cell harvest , wash frozen . 2 . MSC injection MSC thaw diluted Laboratory Cell Gene Therapy ( LTCG ) , transport hospital ward inject intravenously within 1 hour thaw central catheter ( available ) good peripheral vein . A dose 1.5 - 2.0 x 106/kg recipient MSC ideally administer infusion . MSC infuse even number post-thaw cell low . Patients Crohn 's disease receive two injection allogenic MSC 4 week apart ( week 0 4 ) . 3 . Patients Follow 3.1 . Quality control MSC product Quality control MSC product include microscopy , nucleate cell count differential , cell viability testing , microbiology test ( include standard virology , bacterial culture detection mycoplasmal enzyme bioluminescence , endotoxin testing , karyotype FACS analysis ( cell must positive : CD90 &gt; 70 % , CD105 &gt; 70 % , CD73 &gt; 70 % ; negative : CD14 &lt; 5 % , CD34 &lt; 5 % , CD45 &lt; 5 % , CD3 &lt; 1 % ) . 3.2 . Toxicities cell infusion : Potential toxicity associate MSC infusion carefully monitor per institution 's standard document infusion report and/or SAE report form . No dosage modification schedule . In case severe reaction first MSC infusion , second infusion perform . 3.3 . Clinical data The following parameter follow baseline well week 2 , 4 , 8 12 : CDAI level , CRP level , fecal calprotectin level . In addition , duration hospitalization , infection , serious complication , eath survival record . 3.4 . Immunologic data : Immune function patient monitor baseline appropriate interval : nucleate cell count differential ; FACS analysis determination % cell ( total WBC ) marker : CD3+ , CD4+ , CD8+ , CD19+ , CD45RA+ , CD45RO+ , CD56+ , CD3+CD4+ , CD3+CD8+ ; CD3+CD56+ ; CD4+CD45RA+ , CD4+CD45RO+ ; CD3-CD56+ ; regulatory T-cell ( Treg ) level ; immunoglobulin level , Vβ repertoire T lymphocytes ; TRECs quantification T lymphocytes .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Age 18 75 year old Crohn 's disease affect terminal ileum , colon diagnosis confirm accord Lennard Jones criterion Clinically active disease CDAI 220 450 biologically active disease CRP &gt; 5 mg/l and/or fecal calprotectin &gt; 150 microg/g Resistance intolerance mesalazine , steroid , purine analogue , methotrexate , infliximab adalimumab Adequate venous access ( central catheter good peripheral vein ) Willingness sign inform consent enter clinical trial Any condition fulfil inclusion criterion Indication surgery Symptomatic stricture Undrained perianal intraabdominal abscess Change mesalazine dosage within last 4 week , change steroid dosage within last two week , change immunosuppressant dosage within last 3 month , use antiTNF treatment within last two month HIV positive Uncontrolled infection , arrhythmia hypertension Terminal organ failure : Renal : anuria , serious fluid overload , GFR &lt; 30 ml/min , dialysis ; Pulmonary : DLCO &lt; 35 % and/or receive supplementary continuous oxygen ; Hepatic : Fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease ; Cardiac : Symptomatic coronary artery disease cardiac failure require therapy ; ejection fraction &lt; 35 % ; uncontrolled arrhythmia , uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Mesenchymal Stem Cell</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Inflammatory disorder</keyword>
	<keyword>Autoimmune disorder</keyword>
</DOC>